Search results
CNN anchor Sara Sidner to undergo double mastectomy amid breast cancer battle
theGrio via AOL· 3 days agoBlack women in the U.S. have a 4% lower incidence rate of breast cancer compared to white women but are more likely ...
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
Digital Journal· 1 day ago83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian ...
Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024
KTLA-TV Los Angeles· 1 day agoShanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers ...
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to...
Morningstar· 1 day agoWith its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts. A ...
No Improvement in OS With Atezolizumab in Relapsing TNBC
Medscape· 6 days agoEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast ...
Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and...
WKBN 27 Youngstown· 1 day agoLunit will present detailed findings on several innovative studies, including the identification of HER2 ultra-low expression in breast cancer using AI-based ...
... in Combination with anti-PD-1 for First Line Recurrent and/or Metastatic Head and Neck Cancer to...
The Yuma Sun· 1 day agoThe updated interim evaluation (data cut-off: August 31, 2023) of 19 enrolled patients in ASP-1929-181 study suggests that the novel treatment approach of ASP-1929 photoimmunotherapy in combination ...
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and...
FOX 23 News Albany· 1 day agoOncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American ...
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 1 day agoMeeting. Of the 37 patients evaluable for efficacy assessment, the objective response rate (ORR) and...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 2 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...